Latest Healthcare It News

Talius has secured a substantial $850,000 purchase order from New Zealand’s Hato Hone St John, adding 8,000 devices and boosting its recurring revenue by $55,000 annually.

Flagship Investments Limited reported a sharp 24.1% portfolio decline for the year ended 30 June 2026, underperforming the ASX All Ordinaries Index by 21.7 percentage points. Despite this, the company declared a fully franked final dividend of 5.3 cents per share, supported by retained earnings.

Kingfish Limited posted a net loss of NZD 13.6 million for FY2026, underperforming the NZX50 benchmark, but showed early signs of recovery in FY2027. The company re-elected two directors and maintained its focus on quality growth stocks amid a cautious economic outlook.

Resmed delivered a strong FY2026 with 10% revenue growth to $5.7 billion, a 17% rise in non-GAAP EPS, and a 10% dividend hike. Strategic moves include selling MatrixCare and acquiring Noctrix Health.

Wellnex Life has agreed to sell its Pain Away brand to Mentholatum Australasia for up to A$21.3 million, aiming to wipe out debt and sharpen its strategic focus.

Argent BioPharma's licensing partner Splash Beverage Group has launched the US veterinary development program for CannEpil®, targeting companion-animal oncology and chronic pain. Led by industry veteran Dr Hunter Land, the initiative follows a defined FDA regulatory pathway and could broaden CannEpil®’s commercial footprint beyond human neurology.

Integral Diagnostics has installed Jason Martinez as its new CEO, marking a leadership change as the company prepares to present its FY26 results. Martinez brings over 20 years of diagnostic imaging experience and aims to drive growth and innovation following the retirement of long-serving CEO Ian Kadish.

Kinatico Limited reports a robust FY26 with SaaS revenue growth driving total revenue up 9.4% to $35.2 million and net profit after tax soaring 78.5% to $2.0 million, underpinned by its AI-native compliance platform.

Promisia Healthcare is set to acquire Chatswood Retirement Village in Christchurch for $25 million, bolstering its East Christchurch presence and promising immediate earnings accretion.

Lumos Diagnostics has landed a US$767,800 purchase order for its FebriDx rapid test from PHASE Scientific, marking a key step in commercialising its FDA-approved product ahead of the US flu season.

Charter Hall Social Infrastructure REIT (ASX:CQE) reported a 13.1% rise in operating earnings per unit for FY26, driven by strategic acquisitions and strong rental growth, while raising guidance for FY27.

Stakk Ltd's combined pro forma FY2026 revenue with ParaScript has climbed to approximately A$45 million, surpassing earlier forecasts by 9%. Both companies outperformed initial revenue assumptions, setting a stronger baseline ahead of integration benefits.